CORRELATION BETWEEN THE FUCOSE CONTENT / GALACTOSE CONTENT RATIO OF ANTI-RHESUS-D AND ANTI-HLA-DR ANTIBODIES AND THE ADCC ACTIVITY

摘要

Process for preparing a monoclonal, chimeric, humanized or human antibody (Ab) that has a strong effector activity comprises: (a) purifying monoclonal antibodies obtained from different sources, particularly cells, plants and non-human animals, optionally genetically modified or transfected; (b) measuring the levels of fucose (Fu) and galactose (Gal) in the glycan structures at the glycosylation sites in antibody Fc fragments; and (c) selecting Ab in which the Fu:Gal ratio was 0.6 or lower. An independent claim is also included for therapeutic monoclonal antibodies, with strong ADCC (antibody-dependent cellular cytotoxicity) selected by the new process. ACTIVITY : Cytostatic; Virucide; Antibacterial; Antiparasitic; Circulatory. No details of tests for these activities are given. MECHANISM OF ACTION : Passive immunotherapy; induction of ADCC (antibody-dependent cellular cytotoxicity) and of cytokine secretion.